Medistem files patent application for cardiac valve therapy

By Elaine Rigoli

Tampa, Fla., Sept. 15 - Medistem Laboratories, Inc. has filed an application with the U.S. Patent Office for a patent for stem cell therapy for cardiac valvular dysfunction.

Medistem's patent application, submitted by consulting research scientist Thomas E. Ichim, said the invention relates to using stem cells and modified stem cells to induce a therapeutic benefit to a patient suffering from a dysfunction of the mitral, aortic, tricuspid or pulmonary valve.

The company said a discovery of an apparent repair of an aortic valve occurred at the Institute for Cellular Medicine, its affiliated stem cell clinic located in San Jose, Costa Rica.

Significantly, the patient was being treated with adult stem cells for a different medical condition, the Tempe, Ariz., biotechnology company said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.